ArticleFrontiers in oncology2025
Rare primary pleomorphic rhabdomyosarcoma of the thyroid gland with lung and adrenal metastases: a case report and literature review.
Article in Frontiers in oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Primary thyroid pleomorphic rhabdomyosarcoma (PRMS) is an extremely rare and aggressive neoplasm, with only five cases reported in the literature to date. We present the sixth reported case of primary thyroid PRMS and the first case demonstrating distal metastases to the lungs and left adrenal gland in a 71-year-old female. The patient underwent total thyroidectomy with lymphadenectomy, with histopathological evaluation confirming PRMS and demonstrating a highly aggressive biological behavior. The immunophenotypic profile showed strong immunopositivity for skeletal muscle markers, including desmin and vimentin. Further computerized tomography imaging identified a metastasized lesion in the left adrenal gland and a diffuse lung nodular dissemination. The patient received a personalized treatment plan which combined both systemic chemotherapy and radiotherapy. After four cycles of chemotherapy, the patient achieved partial regression of metastatic lesions. The highly aggressive nature of PRMS emphasizes the importance of having individualized and multidisciplinary treatment approaches to such rare cases.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.